A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions

Solid Tumor Clinical Trial

Official title:

A Phase I Study of Repeated Intratumoral Administration of TBI-1401(HF10), a Replication Competent HSV-1 Oncolytic Virus, in Patients With Solid Tumors With Superficial Lesions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02428036
• Other study ID #: TBI1401-01
• Status: Completed
• Phase: Phase 1
• First received: April 16, 2015
• Last updated: June 29, 2017
• Start date: June 2015
• Est. completion date: June 2017

Study information

• Verified date: June 2017
• Source: Takara Bio Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether TBI-1401(HF10), a spontaneously attenuated mutant of Herpes Simplex Virus Type 1 (HSV-1), is safe and tolerable in the treatment of solid tumors with superficial lesions.

Description:

This is an open label, non-randomized, dose escalation Phase I study evaluating the repeated intratumoral administrations of the TBI-1401(HF10), a spontaneously attenuated mutant of HSV-1, in patients with solid tumors with superficial lesions (e.g., malignant melanoma and squamous cell carcinoma of the skin).

The study will evaluate the safety and tolerability of repeated intratumoral administrations of TBI-1401(HF10) at dose levels of 1 x 10^6 TCID50/dose (cohort 1) and 1 x 10^7 TCID50/dose (cohort 2) in Japanese patients. Three patients will be enrolled in each cohort. Patients in the each cohort will receive a total of four intratumoral administrations in the same lesion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: June 2017
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologically confirmed solid tumors with superficial lesions.

• Patients must have unresectable and standard therapies-resistant solid tumors.

• Patients must be = 20 years of age.

• Patients must have a life expectancy = 12 weeks.

• Patients must have measurable non-visceral lesion(s) that are evaluable by the mWHO response criteria.

• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

• Patients must have adequate key organ function (bone marrow, heart, lung, liver, renal, etc), as defined as

• Absolute neutrophil count = 1,500/µL.

• Platelet count = 100,000/µL.

• Total bilirubin levels = 1.5 x upper limit of normal (ULN).

• AST/ALT levels = 2.5 x ULN, or = 5 x ULN if liver metastases are present.

• creatinine = 1.5 x ULN.

• creatinine clearance (calculated) = 60 mL/min/1.73 m^2 for patients with creatinine > 1.5 x ULN.

• Patients must have passed 4 weeks after the completion of prior therapy [except bone metastasis therapy], or passed 8 weeks if immuno checkpoint inhibitor was treated.

• Patients must be able to understand and willing to sign a written informed consent document.

Exclusion Criteria:

• Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders.

• Patients with Grade 2 adverse events Grade 2 or greater, except alopecia, resulting from anticancer agents administered more than 4 weeks prior to TBI-1401(HF10) administration.

• Patients receiving anti-herpes medication [except local treatment such as ointment].

• Patients receiving steroids or immunosuppressive agents [except inhaled steroid].

• Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection.

• Patients receiving anti-platelet medication.

• Patients receiving anti-coagulation medication.

• Patients with presence or medical history of central nervous system metastasis.

• Patients with Grade = 2 pre-existing neurologic abnormalities (CTCAE version 4.0).

• Patients with severe cardiac disorder or abnormal cardiac rhythm.

• Patients with psychiatric disorder or drug dependency which affects informed consent.

• Pregnant or breastfeeding women; women or men, having normal reproductive potential, who disagree with the protection of pregnancy within the timeframe of the study.

• Patients received any other investigational products within 4 weeks, or within 8 weeks if immuno checkpoint inhibitor was treated.

• Patients would limit compliance with study requirements, as determined by the investigator.

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Biological:
• TBI-1401(HF10)
Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^6 TCID50/mL.
• TBI-1401(HF10)
Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^7 TCID50/mL.

Locations

Country	Name	City	State
Japan	National Cancer Center Hospital	Chuo-ku	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Takara Bio Inc.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in cytokine profiles in serum	Evaluation of cytokine profiles in serum by immunoassay.	up to Week 12
Other	Change in antitumor T-cell reactivity in serum	Antitumor T-cell reactivity in serum will be evaluated by flow cytometry.	up to Week 12
Other	Change in regulatory T-cell (Treg) population in serum	Treg population in serum will be evaluated by flow cytometry.	up to Week 12
Other	Histopathological response with TBI-1401(HF10) administrated tumor	Core biopsies will be performed to evaluate the histopathological response with TBI-1401(HF10) administrated tumor.	at Week 12
Primary	Safety and tolerability (CTCAE version 4.0).	Adverse events will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0).	up to Week 16
Secondary	Overall tumor response (modified World Health Organization response criteria)	Overall tumor response will be evaluated by modified World Health Organization (mWHO) response criteria in the measurable target lesion(s) and unmeasurable/evaluable target lesion(s).	at Week 12
Secondary	Levels of antibody to HSV-1	Anti-HSV-1 antibodies will be assessed in serum.	up to Week 12